Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mark Tomishima"'
Autor:
Philip Lee, Assen Roguev, Cesar Juarez, Michelle Hung, Frances D Liu, Yin Yin Chong, Russell M Gordley, Mark Tomishima, Jessica M Haverkamp, Panos Douvaras, Alex Danza, Monika Avina, Timothy K Lu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/9faca5d236fd461fb3c9807b5039d1ea
Autor:
Marcus Gainer, Assen Roguev, Michelle Hung, Rebecca Cottman, Yin Yin Chong, Russell M Gordley, Mark Tomishima, Monika Avina, Timothy K Lu, Vanessa Johnson, Eren Chu, Joseph Sperling, Brett Kiedaisch, Raghav Kannan, Chandra Verma, Chew-Li Soh, Conor McAuliffe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e5f99ced4a4d4c5abf261126cd6fc652
Autor:
Sadaf Amin, Brandoch Cook, Ting Zhou, Zaniar Ghazizadeh, Raphael Lis, Tuo Zhang, Mona Khalaj, Miguel Crespo, Manuradhi Perera, Jenny Zhaoying Xiang, Zengrong Zhu, Mark Tomishima, Chengyang Liu, Ali Naji, Todd Evans, Danwei Huangfu, Shuibing Chen
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
GLIS3 mutations are associated with type 1, type 2, and neonatal diabetes. Here, the authors generate mono-hormonal glucose-responding pancreatic β-like cells in vitro and through a screen identify a drug that rescues pancreatic β-like cell death i
Externí odkaz:
https://doaj.org/article/c14e49f0fd174b1ebce0f8854fb56b94
Autor:
Erika Brunet, Didier Surdez, Olivier Delattre, Thomas G.P. Grünewald, Maria Jasin, Mark Tomishima, Sophie Kaltenbach, Lucile Couronné, Isabelle Janoueix-Lerosey, Cécile Pierre-Eugène, Carine Giovannangeli, Anne De Cian, Benjamin Renouf, Patrick Revy, Sakina Zaïdi, Loelia Babin, Maxime Heintzé, Sandrine Grossetête, Anna Sole
Ewing sarcoma is characterized by pathognomonic translocations, most frequently fusing EWSR1 with FLI1. An estimated 30% of Ewing sarcoma tumors also display genetic alterations in STAG2, TP53, or CDKN2A (SPC). Numerous attempts to develop relevant E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23b462046e012718bca74554bcfef791
https://doi.org/10.1158/0008-5472.c.6513129.v1
https://doi.org/10.1158/0008-5472.c.6513129.v1
Autor:
Erika Brunet, Didier Surdez, Olivier Delattre, Thomas G.P. Grünewald, Maria Jasin, Mark Tomishima, Sophie Kaltenbach, Lucile Couronné, Isabelle Janoueix-Lerosey, Cécile Pierre-Eugène, Carine Giovannangeli, Anne De Cian, Benjamin Renouf, Patrick Revy, Sakina Zaïdi, Loelia Babin, Maxime Heintzé, Sandrine Grossetête, Anna Sole
SupReferences+SupMAt&Met+Suptables+SupFig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a8a17d1c9f12fd5960c967e79eef0e6
https://doi.org/10.1158/0008-5472.22428768
https://doi.org/10.1158/0008-5472.22428768
Autor:
Mark Tomishima, Nicole Dubois, Leili Sarrafha, Christoph Schaniel, Shuibing Chen, Damelys Calderon, Nadeera Wickramasinghe
While much progress has been made in understanding early cardiac development, the precise mechanisms that specify the different cardiomyocyte subtypes remain poorly understood. Recent data from our lab have shown that transient Foxa2 expression ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bcadad3edcac65e742e1e592eeabfdb
https://doi.org/10.1101/2021.07.18.452860
https://doi.org/10.1101/2021.07.18.452860
Autor:
Mark Tomishima, Agnete Kirkeby
Publikováno v:
Journal of Parkinson's Disease
Tomishima, M & Kirkeby, A 2021, ' Bringing Advanced Therapies for Parkinson's Disease to the Clinic : The Scientist's Perspective ', Journal of Parkinson's Disease, vol. 11, pp. S135-S140 . https://doi.org/10.3233/JPD-212685
Tomishima, M & Kirkeby, A 2021, ' Bringing Advanced Therapies for Parkinson's Disease to the Clinic : The Scientist's Perspective ', Journal of Parkinson's Disease, vol. 11, pp. S135-S140 . https://doi.org/10.3233/JPD-212685
After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson
Publikováno v:
Stem Cells & Development; Nov2011, Vol. 20 Issue 11, p1889-1900, 12p